Nektar Therapeutics (NKTR)
NKTR moved a median of +0.07% 30 minutes after news, and 0.00% by the close. How NKTR actually reacts to news — the realized, point-in-time move the market made, measured across 898 labeled events over the last three years with zero look-ahead.
NKTR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.11% | 54% | 887 |
| 30-min | +0.07% | 53% | 892 |
| 60-min | -0.13% | 47% | 893 |
| to close | 0.00% | 49% | 888 |
| Middle 50% of NKTR reactions | -1.05% to +1.20% |
|---|---|
| Median reaction (30-min) | +0.07% |
| Measured reactions | 898 |
Half of all Nektar Therapeutics news events land between -1.05% and +1.20% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NKTR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -1.28% | 27% | -0.33% |
| Coverage initiations | 37 | 0.00% | 49% | -0.76% |
| Rating reiterations | 45 | +0.08% | 56% | -0.49% |
| Price-target raises | 15 | -0.09% | 47% | -0.30% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how NKTR ranks against every other measured name →
That’s how NKTR usually reacts — get an email when it moves on news →Email me when NKTR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NKTR's baseline. Nothing else.
Recent NKTR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.08% | -0.32% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.12% | -0.81% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -1.14% | -2.66% | |
| Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.33% | +1.00% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.29% | -0.72% | |
| Form 8-K NEKTAR THERAPEUTICS For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -0.73% | -15.10% | |
| New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Press release | PR Newswire | -0.73% | -15.10% | |
| New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis | Press release | PR Newswire | +1.40% | +0.57% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.02% | +1.54% | |
| Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026 | Press release | PR Newswire | +0.49% | +5.96% | |
| Form 8-K NEKTAR THERAPEUTICS For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +0.75% | -4.53% | |
| Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.49% | +5.96% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.28% | +2.29% | |
| Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.83% | -2.47% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.16% | +0.32% | |
| Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.14% | -1.91% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.14% | -1.21% | |
| Form 8-K NEKTAR THERAPEUTICS For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +0.08% | -2.37% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.29% | +1.81% | |
| Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +2.44% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.06% | -0.64% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.08% | -0.06% | |
| Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -0.08% | -0.06% | |
| Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis | Press release | PR Newswire | +0.67% | -0.03% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.04% | +0.93% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.28% | +0.96% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.42% | +0.48% | |
| Form 10-Q NEKTAR THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.30% | -1.32% | |
| Form S-8 NEKTAR THERAPEUTICS | SEC filing · Form S-8 | SEC EDGAR | -1.71% | +0.81% | |
| Form 8-K NEKTAR THERAPEUTICS For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +1.30% | -1.32% | |
| Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.01% | -0.91% | |
| Nektar Therapeutics Announces Second Quarter 2026 Financial Results | Press release | PR Newswire | +1.30% | -1.32% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.23% | — | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.25% | +0.14% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -2.43% | -0.18% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.01% | +1.10% | |
| Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets | Press release | PR Newswire | +0.52% | -0.72% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +2.11% | +0.49% | |
| Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +2.11% | +0.49% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.75% | +0.96% | |
| Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis | Press release | PR Newswire | +0.23% | +6.60% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.37% | -4.32% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.50% | -0.61% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -2.09% | -1.99% | |
| Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.58% | -0.69% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.38% | +6.99% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.03% | -1.03% | |
| Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +1.11% | +3.38% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.31% | -2.53% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.11% | +0.08% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NKTR section they belong to.
Where else NKTR is measured.
NKTR earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| TROVAGENE (TROV) | 906 | -0.52% | 40% |
| KemPharm, Inc. (KMPH) | 901 | -0.21% | 40% |
| Tandem Diabetes Care, Inc. (TNDM) | 895 | +0.13% | 57% |
| Flexion Therapeutics, Inc. (FLXN) | 891 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Nektar Therapeutics's median reaction calculated?
Every labeled NKTR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 898 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of NKTR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NKTR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.